Britain crashes out of favor with US pharmaceutical executives
The biotech industry is a pillar of the knowledge economy, with governments around the world investing heavily to attract capital and develop a highly skilled workforce. Britain has historically enjoyed privileged status for US companies looking to expanding into Europe, offering a common language, world-class talent, a reputation of excellence in clinical research and easy access to the European medicines regulatory agency.
We surveyed C-suite biotech executives in pre-eminent US companies. How do they see the European pharmaceutical market changing? Is it now overshadowed by the rapidly expanding Asian market? How is Brexit impacting Britain’s status as a launchpad into Europe?
The results of our research are summarized in the infographic below.